Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Allarity Therapeutics has expanded its Phase 2 clinical trial of the oral cancer drug stenoparib to include three distinct groups of advanced ovarian cancer patients.